Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study

SIMPLE SUMMARY: Patients suffering from metastasized melanoma can be treated with three different combinations of tablets (“targeted therapy”), with similar efficacy but different side effect profiles. When one of the combinations is not tolerated well, their physicians may switch to a different com...

Descripción completa

Detalles Bibliográficos
Autores principales: Salzmann, Martin, Wald, Alexander, Stege, Henner, Loquai, Carmen, Zimmer, Lisa, Hayani, Kinan M., Heinzerling, Lucie, Gutzmer, Ralf, Enk, Alexander H., Hassel, Jessica C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001327/
https://www.ncbi.nlm.nih.gov/pubmed/36900217
http://dx.doi.org/10.3390/cancers15051426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001327/
https://www.ncbi.nlm.nih.gov/pubmed/36900217
http://dx.doi.org/10.3390/cancers15051426

Ejemplares similares